Otsuka’s Abilify MyCite, the first digital pill, is set to hit the market with a $1,650 per month price tag and will first be available to patients with schizophrenia and bipolar disorder covered by Medicaid, according to a STAT report.
According to the report, a sensor is lodged in each pill which can notify doctors or caregivers when it has been swallowed.
The U.S. Food and Drug Administration approved the treatment last year.
The limited rollout, Otsuka’s Andrew Wright tells STAT, gives the drugmaker a better opportunity to zero in on the response.
“We believe having fewer people treated initially really allows us to listen hard and focus in on the patients, the prescribers, and the health plans,” he said.
Click here to read the full report on STAT. (Paid subscription required)